Lancet Oncol. 2018 Sep 10. pii: S1470-2045(18)30579-5. doi: 10.1016/S1470-2045(18)30579-5. [Epub ahead of print] Camrelizumab for nasopharyngeal carcinoma: a new hope? Kwong DLW1.Author information1Department of Clinical Oncology, University of Hong Kong, Pokfulam, Hong Kong, Special Administrative Region, China. Electronic address: dlwkwong@hku.hk. Wenfeng Fang and colleagues 1 report on two phase 1 studies of the programmed cell […]
Lawrence Young (University of Warwick, United Kingdom)“The Future of NPC Research: Opportunities and Challenges” Key questions relevance of epithelial infection to EBV’s natural history Role of EBV strain variation Precise contribution of EBV latent and lytic genes Contribution of the microenvironment Targeting EBV for … What’s special about the NPC cell and its progenitor? lymphoma-epithelium
Tak Mak (Princess Margaret Cancer Centre, University Health Network, Canada)“Beyond Targeting Oncogenes: Future Anti-Cancer Strategies” Tak Mak (Princess Margaret Cancer Centre, University Health Network, Canada)“Beyond Targeting Oncogenes: Future Anti-Cancer Strategies” – 1983, Discover T cell receptor, 1995- published a landmark paper on the function of CTLA4 By the turn of the last century chemotherapeutic agents
Brigette Ma (The Chinese University of Hong Kong, Hong Kong SAR China)“Immune Checkpoint Inhibitor in the Treatment of Nasopharyngeal Carcinoma: A Clinical Overview” – The blue dots in HE (TME lymphocytes !!)– Co-inhibitory ICPs are inductively and have immunosuppressive fun it (early: CTLA4 dampens T-cell priming; late: PDL1 act on T-effectors in TME)What’s the evidence
Han Chong Toh (National Cancer Centre Singapore, Singapore)“Cellular Immunotherapy for Nasopharyngeal Cancer: Learning from the Past for a Better Tomorrow” Tetrament of metastatic NPC with autologous dendritic cells transfigured with adenoviral veryor (AD5F35) expressing LMP1 and LMP2 genes in patients (NPC vaccine patient 004 –> partial response; knowledge is of no value unless ups put
Graham Taylor (University of Birmingham, United Kingdom)“The NPC Immunotherapy Landscape” Broad CD8+ and CD4+ T cell responses to vaccination in ex Vito ELIspot immune assays– weal pre-existing EBVNA1 and LMPO2 T-cell– Vaccination simulates multiple CD8+ and CD4+ T cell responses within an individual; lpatuens– Anti-tumor T cell responses before vaccination– 95% T celll go to
Rajiv Khanna (QIMR Berghofer Medical Research Institute, Australia)“Adoptive T Cell Therapy for NPC: Immune Correlates to Immune Contexture” Collaborates with Victor Lee, Dora Kwong, Hohn Nichols, Vivian Li, Daniel Chua, Randall ‘Tis Janice Tsang … at HKU) 2017/10/20 second CD19 CAR-T NPC T cell immunotherapy in the past 10 years Singapore group Adoptive T cell
Lillian Siu (Princess Margaret Cancer Centre, Canada)“Immune and Other Biomarkers of Resistance to Anti-PD1 Therapy in NPC” PDL1 in NPC, Limitation of ORR as a surrogate of benefit with IO therapies Other buiomarkers of interest (HLA-I, TMA, immunoprofuiling, radio is signatures, microbiome) HSC et al. PD-L1 >= 1% tumor cells or TILS (22C3) J Clin
Troy Messick (The Wistar Institute, USA)“Development of an EBNA1 Inhibitor for the Treatment of NPC: Toward First-in-Human Studies” EBNA1 is master regulator of ENBV latency ENA1 is the only viral protein expressed in all EBV cancers EBNA1 is required for cell transformation and tumorigenesius EBNA1 structure is now and druggable No EBNA1 orthologs in human
Anne Lee (The University of Hong Kong, Hong Kong SAR China & The University of Hong Kong at Shunzen) “Challenges and Novel Approaches in Radiotherapy for Nasopharyngeal Carcinoma” HKNPC1301 study on IMRT (2001-2010) to further improve tomorrow control for poor risk group IMRT: parotid sparing (randomized trials on IMRT (late toxicity following IRT) Radiotherapy –